Ovid Therapeutics Net Debt Growth & History (OVID)
Ovid Therapeutics's net debt was $266,000 for fiscal 2025.
View full Ovid Therapeutics company overviewOvid Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $266,000 | $11.8M | — |
| 2024 | 2024-12-31 | −$11.5M | −$506,000 | — |
| 2023 | 2023-12-31 | −$11.0M | $17.3M | — |
| 2022 | 2022-12-31 | −$28.3M | $159.5M | — |
| 2021 | 2021-12-31 | −$187.8M | — | — |
Ovid Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $15.7M | — |
| Q1 2026 | 2026-03-31 | −$81.0M | −$74.3M | — |
| Q4 2025 | 2025-12-31 | $266,000 | $11.8M | — |
| Q3 2025 | 2025-09-30 | −$6.8M | −$6.9M | — |
| Q2 2025 | 2025-06-30 | −$14.3M | −$12,000 | — |
| Q1 2025 | 2025-03-31 | −$6.7M | $8.4M | — |
| Q4 2024 | 2024-12-31 | −$11.5M | −$506,000 | — |
| Q3 2024 | 2024-09-30 | $58,000 | $41.2M | — |
| Q2 2024 | 2024-06-30 | −$14.3M | $41.0M | — |
| Q1 2024 | 2024-03-31 | −$15.1M | $31.5M | — |
| Q4 2023 | 2023-12-31 | −$11.0M | $17.3M | — |
| Q3 2023 | 2023-09-30 | −$41.1M | $869,528 | — |
| Q2 2023 | 2023-06-30 | −$55.3M | $1.6M | — |
| Q1 2023 | 2023-03-31 | −$46.5M | $104.2M | — |
| Q4 2022 | 2022-12-31 | −$28.3M | $159.5M | — |
| Q3 2022 | 2022-09-30 | −$42.0M | — | — |
| Q2 2022 | 2022-06-30 | −$56.8M | — | — |
| Q1 2022 | 2022-03-31 | −$150.8M | — | — |
| Q4 2021 | 2021-12-31 | −$187.8M | — | — |
Ovid Therapeutics net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Ovid Therapeutics's net debt increased from −$187.8M to $266,000, a change of $188.1M. The latest reported quarter, Q2 2026, shows $1.4M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ovid Therapeutics source filings ↗